Core Viewpoint - The article discusses the evolving landscape of the medical device industry in China, highlighting the importance of business development (BD) strategies that go beyond mere numbers to encompass strategic partnerships, market expansion, and technological integration [1][24]. Group 1: Key Trends in Medical Device BD - The primary keywords for the period from July to September include cross-border introduction and global distribution, strategic cooperation, and capital and cross-industry integration [2]. - Companies are accelerating market expansion and ecosystem building through transactions across various fields, including cardiovascular, neuro-intervention, ophthalmology, IVD, and critical care [3]. Group 2: Representative Events - A total of 20 significant events were summarized, showcasing a "multi-line advancement" scenario in the industry [4]. - Notable collaborations include: - Nanjing Jianxin Medical and Heqi Family Office focusing on medical device R&D and wealth management [6]. - Olympus and Xingchenhai Medical signing a global distribution agreement for disposable urology products [6]. - He’s Eye Group and Zeiss China Medical forming a strategic partnership to enhance ophthalmic surgical technology [6]. Group 3: Cross-Border and Global Distribution - Cross-border transactions remain a hot topic, with domestic companies leveraging global markets for growth while foreign giants introduce Chinese innovations [9]. - The partnership between Ruichao Dinkai Group and Beijing Amite focuses on vascular intervention products, marking a new phase in safety standards [7]. Group 4: Strategic Cooperation and Channel Expansion - Strategic cooperation is increasingly focused on building ecosystems rather than single product breakthroughs, with companies forming partnerships in fields like ophthalmology, IVD, and diagnostics [19]. - The collaboration between Wanfu Biological and Beiden Medical aims to match products with non-public medical channels effectively [15]. Group 5: Capital Support and Cross-Industry Integration - Capital is becoming an invisible driver of medical device BD, with partnerships exploring new models for medical device distribution [20]. - The collaboration between Beijing Huamai Supply Chain Management and Hongyi Consulting aims to create a one-stop service for medical device distribution [20]. Group 6: Smart Hospitals and Full-Chain Coordination - The focus on smart hospitals and full-chain coordination is becoming a priority for large enterprises, integrating supply chains, academic promotion, and clinical needs [23]. - Collaborations like that of Ruibo Zehou Technology and China National Pharmaceutical Group aim to develop automated systems for smart hospitals [21]. Conclusion - The medical device industry in China is transitioning from a "single product-driven" phase to a more diversified approach supported by capital, channels, and ecosystems, indicating a long-term growth trajectory [24].

Group 1 - Business Development (BD) is a significant trend in the domestic medical device industry, with a notable increase in BD transactions for innovative drugs, reaching a total of $60.8 billion in the first half of the year, surpassing the total for 2024 [1] - The Chinese government is promoting the development of domestic medical devices, with a focus on high-end medical equipment and technologies such as medical robots and AI medical devices, as outlined in the announcement released in July 2025 [2] - There is a fundamental difference in the evaluation systems and investment models between innovative drugs and medical devices, with medical devices requiring more extensive market and academic investment for recognition in different markets [3] Group 2 - The current BD model for medical devices is not suitable for a simple license-out approach due to the high dependency on usage scenarios and the experience of practitioners, which complicates the management and control of subsequent clinical trials and registrations [4] - Although the current BD model for innovative drugs may not fit medical devices, there are still BD transactions occurring in the medical device sector, such as the joint venture established between China Medical Device Co., Ltd. and GE Healthcare China [5] - The recently published "Medical Device BD White Paper 2025" indicates that BD in the medical device sector encompasses various transaction activities, including technology licensing, joint development, and strategic investments, with a focus on the actual product deployment [6] Group 3 - The trend in medical device BD is shifting from single transactions to a more structured resource allocation system, with an increasing willingness among investors and partners to engage in the early stages of product development and registration [7]

Core Viewpoint - The article emphasizes the importance of Business Development (BD) in the medical device industry, highlighting that success often relies on strategic transactions rather than solely on product success [1][2]. Group 1: Importance of BD - BD is not merely an additional capability but a structural advantage that should be integrated from product design, registration strategy, and market validation [2]. - The medical device industry's rules are changing, necessitating a readiness to engage in transactions [2]. Group 2: Key Scenarios for Medical Device Companies - The white paper aims to provide practical guidance for medical device companies on how to accelerate growth and navigate challenges [1]. - It addresses various scenarios such as finding the first business through licensing, designing cooperation structures for international expansion, and integrating investment with sales during financing [3]. Group 3: Structure of the White Paper - The white paper is divided into six chapters covering topics from product authorization, strategic partnerships, overall mergers and acquisitions, to enhancing a company's "tradeability" and future trends [2].

Core Viewpoint - The article emphasizes the importance of business development (BD) capabilities in the medical device industry, highlighting that many excellent companies struggle to secure their first transaction due to a lack of understanding of how to engage in business collaborations [2][4]. Summary by Sections Purpose of the White Paper - The white paper aims to address the challenges faced by medical device companies in executing transactions and to provide practical guidance on business development [3][4]. Content of the White Paper - The white paper is designed as a practical knowledge manual for medical device companies, investors, and industry participants, focusing on key scenarios such as business cooperation, product licensing, strategic investment, and mergers and acquisitions [2][7]. - It is not merely a marketing document for investors but a reference guide based on real operational issues, detailing how to negotiate, what to discuss, and common pitfalls to avoid [2][7]. Target Audience - The white paper is intended for a broad audience, including: - Medical device BD professionals who need a comprehensive understanding of structured transaction capabilities [7]. - Investment institutions and BD teams looking to engage in the medical device sector [12]. - Product teams aiming to expand internationally but lacking methodological support [12]. Key Insights and Trends - The white paper discusses various collaboration models, including product licensing, equity investment with sales binding, and overall exit strategies through mergers and acquisitions [7]. - It includes case studies, such as the acquisition of MAKO by Stryker and strategies employed by Chinese companies in investment and sales transactions [7]. - Future trends in medical device BD are highlighted, including international expansion, combination transactions, early-stage positioning, and team function upgrades [7].